Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 26, 2007

Graffinity and Amgen Enter into Drug Discovery Research Agreement

  • Graffinity Pharmaceuticals entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets.

    Amgen will gain access to Graffinity’s proprietary fragment-based drug discovery technology, which uses chemical microarrays to screen for small molecule fragments that bind to a variety of drug targets that play a key role in major human diseases. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »